Support our work
Decorative header background

Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease

Publication year 2014
Published in Movement disorders : official journal of the Movement Disorder Society
Authors Y.D. van der Werf, Chris Vriend, Anna H Nordbeck, Jan Booij, Tommy Pattij, Pieter Voorn, Pieter Raijmakers, Elisabeth M J Foncke, Elsmarieke van de Giessen, Henk W Berendse, Odile A van den Heuvel,

Impulse control disorders (ICD) are relatively common in Parkinson’s disease (PD) and generally are regarded as adverse effects of dopamine replacement therapy, although certain demographic and clinical risk factors are also involved. Previous single-photon emission computed tomography (SPECT) studies showed reduced ventral striatal dopamine transporter binding in Parkinson patients with ICD compared with patients without. Nevertheless, these studies were performed in patients with preexisting impulse control impairments, which impedes clear-cut interpretation of these findings. We retrospectively procured follow-up data from 31 medication-naïve PD patients who underwent dopamine transporter SPECT imaging at baseline and were subsequently treated with dopamine replacement therapy. We used questionnaires and a telephone interview to assess medication status and ICD symptom development during the follow-up period (31.5 ± 12.0 months). Eleven patients developed ICD symptoms during the follow-up period, eight of which were taking dopamine agonists. The PD patients with ICD symptoms at follow-up had higher baseline depressive scores and lower baseline dopamine transporter availability in the right ventral striatum, anterior-dorsal striatum, and posterior putamen compared with PD patients without ICD symptoms. No baseline between-group differences in age and disease stage or duration were found. The ICD symptom severity correlated negatively with baseline dopamine transporter availability in the right ventral and anterior-dorsal striatum. The results of this preliminary study show that reduced striatal dopamine transporter availability predates the development of ICD symptoms after dopamine replacement therapy and may constitute a neurobiological risk factor related to a lower premorbid dopamine transporter availability or a more pronounced dopamine denervation in PD patients susceptible to ICD.

Support our work!

The Friends Foundation facilitates groundbreaking brain research. You can help us with that.

Support our work